Submitted by Anonymous (not verified) on 29 November 2023 - 14:30
Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised
Source: